MHRA 2030 Strategy sets direction for AI devices and lifecycle data

What Changed

The Medicines and Healthcare products Regulatory Agency announced its 2030 Strategy in a press release dated 14 October 2026. It sets out plans to translate scientific and technological innovation into better patient outcomes and faster access to safe, effective treatments.

For medical devices, priorities include an adaptive framework for AI, better use of device data and lifecycle traceability. The announcement presents strategic commitments rather than specifying newly effective compliance obligations.

Who Is Affected

The strategy is relevant to digital-health and AI medical-device developers, other device manufacturers, clinical research sponsors, healthcare professionals and patients across all four UK nations.

Start-ups and smaller companies are also addressed through a planned targeted voucher scheme intended to reduce regulatory barriers. The release does not provide application conditions or a launch date.

Regulatory and Technical Implications

A planned MHRA Centre for AI and Digital Health would clarify regulatory expectations for developers of digital and AI-driven medical devices and medicines. Separately, the agency commits to creating a modern, adaptive framework for AI as a medical device.

Data commitments include improving device identification and lifecycle traceability, using AI to analyse real-world data and detecting potential safety issues earlier. MHRA also plans to make Yellow Card adverse-event reporting simpler and quicker for patients and healthcare professionals.

International priorities include expanded reliance and recognition routes, collaboration with the US FDA and continued recognition of CE-marked devices. The release does not announce new CE-recognition expiry dates or extensions.

Manufacturer Actions

Key developments for manufacturers to monitor are the AI framework’s detailed provisions, expectations from the planned centre and implementation information on device data. The strategy alone should not be treated as establishing a new conformity assessment route or technical-documentation requirement.

The announcement also proposes increased criminal enforcement capacity against illegal medicines and medical-device activity. It does not set a new manufacturer reporting deadline.

Confirmed Dates

The release is dated 14 October 2026, and the strategy’s target horizon is 2030. Publication of an AI Medicines Development Action Plan is planned for 2027.

A Women’s Health Plan and refreshed Patient and Public Involvement and Engagement Plan are planned for 2026. No implementation dates are specified for the AI and Digital Health centre or the AI medical-device framework.

Official Source

This article is based on MHRA’s GOV.UK press release, “MHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines.”

https://www.gov.uk/government/news/mhra-2030-strategy-to-modernise-patient-centred-regulation-for-the-era-of-ai-and-personalised-medicines